Ohkusa Toshifumi, Sato Nobuhiro
Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
J Gastroenterol Hepatol. 2005 Mar;20(3):340-51. doi: 10.1111/j.1440-1746.2004.03472.x.
A variety of medicines have been used for the treatment of inflammatory bowel disease. Antibacterial therapy has demonstrated promise by both improving symptoms and causing disease remission. The mechanism is unknown, but may be related to either eliminating a key pathogen, decreasing the number of bacterial secretory products or defective particles, a direct immunomodulating effect, or reducing secondary bacterial invasion. Historically, a large number of bacterial species have been suspected as being major contributors to the etiology of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Many trials of antibacterial agents have been carried out in inflammatory bowel disease. Recently, treatments have focused on Gram-negative anaerobes and mycobacteria. The present paper briefly reviews antimicrobial and antimycobacterial treatments in inflammatory bowel disease.
多种药物已被用于治疗炎症性肠病。抗菌治疗已显示出有望改善症状并使疾病缓解。其机制尚不清楚,但可能与消除关键病原体、减少细菌分泌产物或缺陷颗粒的数量、直接免疫调节作用或减少继发性细菌入侵有关。从历史上看,大量细菌种类被怀疑是炎症性肠病(包括溃疡性结肠炎和克罗恩病)病因的主要促成因素。许多抗菌药物试验已在炎症性肠病中进行。最近,治疗重点集中在革兰氏阴性厌氧菌和分枝杆菌上。本文简要综述了炎症性肠病的抗菌和抗分枝杆菌治疗。